Loading...
Entheon Biomedical Corp.
ENBI.CN•CNQ
HealthcareBiotechnology
$0.10
$-0.01(-12.50%)
Entheon Biomedical Corp. (ENBI.CN) Stock Overview
Explore Entheon Biomedical Corp.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.03
EPS Growth
$-0.03
Operating Margin
0.00%
ROE
-133.11%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ENBI.CNAnalyst Recommendations details for ENBI.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
CEO
Mr. Timothy Ko
Employees
1
Headquarters
999 West Broadway, Vancouver, BC
Founded
2018